Lionco Pharmaceutical Group Co.,Ltd.

Shanghai Stock Exchange 603669.SS

Lionco Pharmaceutical Group Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2023: USD 63.44 M

Lionco Pharmaceutical Group Co.,Ltd. Total Non-Current Liabilities is USD 63.44 M for the year ending December 31, 2023, a 4.76% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Lionco Pharmaceutical Group Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 60.56 M, a -5.38% change year over year.
Lionco Pharmaceutical Group Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 64.00 M, a -17.23% change year over year.
Lionco Pharmaceutical Group Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 77.33 M, a 170.74% change year over year.
Lionco Pharmaceutical Group Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 28.56 M, a 5.84% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Shanghai Stock Exchange: 603669.SS

Lionco Pharmaceutical Group Co.,Ltd.

CEO	Ms. Ling Ping Tao
IPO Date	May 28, 2015
Location	China
Headquarters	Commercial and Residential Building 2
Employees	475
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Non-Alcoholic Beverages Personal Care Pet Food Vaccines

Description

Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in China. The company offers nutrition, antimicrobial, antiviral, digestion, cardiovascular, detoxification, anti-tumor, and other products. It also operates research institutes that specialize in the research of chemical drugs, natural medicines, and biological drugs. Lionco Pharmaceutical Group Co., Ltd. was founded in 2003 and is based in Shannan, China.

Key trends

Past 5 years